Home › Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014
 

Keywords :   


Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014

2014-09-29 11:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with data advanced early

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.06Atlantic Tropical Weather Outlook
28.06Learning to listen to nursery pigs
28.06Incomes have risen 'at a crawl' says think tank
28.06Eastern North Pacific Tropical Weather Outlook
28.06Are rainy days ahead for cloud computing?
28.06Electric car battery charges in under five minutes in track test
28.06Debt relief orders can write off up to 50,000
27.06Strike could force Tata plant to shut next week
More »